uniQure

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Morgan Stanley

Netflix

OrganiGram Holdings Inc.

The RealReal

Stitch Fix

Syndax Pharmaceuticals

As stocks keep pushing to highs again and again, where can you find smart stocks to buy right now? Check out these 7 excellent options.

7 Stocks to Buy With Over 20% Upside From Current Levels

CEO, CFO, Managing Director of Uniqure Nv (30-Year Financial, Insider Trades) Matthew C Kapusta (insider trades) sold 8,000 shares of QURE on 07/17/2019 at an average price of $71.45 a share.

Uniqure Nv (QURE) CEO, CFO, Managing Director Matthew C Kapusta Sold $571,600 of Shares

Steady progress with experimental gene therapies gave investors reasons to cheer.

What Drove uniQure 171% Higher in the First Half of 2019

Adverum Biotechnologies

Voyager Therapeutics

Good news has a way of attracting suitors.

3 Biotechs That Have Doubled This Year (Acquisition Next?)

Blueprint Medicines

Incyte

Verastem

A few biotechs focused on oncology or gene therapies are potential acquisition targets following the announcement by Pfizer to acquire Array BioPharma.

Cancer/Gene Therapy Biotechs in Focus After Pfizer-Array Deal

Spark Therapeutics

Roche Holding AG

Gene therapy player Uniqure could head to the auction block, an analyst said Monday as shares of the biotech company popped. He also said Roche's plan to buy Spark Therapeutics could falter.

Why This Gene Therapy Stock Looks Like A Sure Takeover Bet: Analyst

uniQure NV (NASDAQ: QURE) shares are trading higher by 6% in Monday's pre-market session following a Bloomberg report the company is exploring strategic options, including a potential sale.

Report: uniQure Could Put Itself Up For Sale

Investors need to pay close attention to uniQure (QURE) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in uniQure (QURE) Stock?

Advanced Micro Devices

Kirkland Lake Gold

Snap

These four stocks in the high-momentum technology, biotech and mining areas are on the move.

4 Momentum Stocks to Watch: AMD, KL QURE & SNAP

AMD and 3 more momentum stocks to watch

uniQure (QURE) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

uniQure (QURE) Jumps: Stock Rises 8.9%

CRISPR Therapeutics

Biotech stocks targeting gene therapy are going to be huge. Here are 3 gene therapy stocks to buy that have a ton of potential.

3 Top Gene Therapy Stocks That Could Soar

UniQure stock approached a breakout Friday after its experimental gene therapy showed improving promise in hemophilia B treatment. Shares are consolidating with a buy point at 69.70.

This Gene Therapy Stock Is Nearing A Breakout On Its Hemophilia B Study

REGENXBIO

Solid Biosciences

Gene therapy continues to be in focus given the recent spate of deals and acquisitions. We highlight four stocks, which have promising gene therapy candidates in their pipeline.

4 Gene Therapy Players Likely to Become Buyout Targets in 2019

News for uniQure Stock (QURE)